CAJ | 학술논문

华法林是临床应用最广泛的口服抗凝药物之一。但由于其有效治疗范围窄，个体差异大，所以如何安全、合理使用华法林成为研究者关注的重点和难点。近年来的研究发现，基因多态性决定了华法林有效治疗剂量的个体差异。本文拟从CYP2C9、VKORC1及APOE等基因多态性方面阐述华法林对个体用药的影响。
화법림시림상응용최엄범적구복항응약물지일。단유우기유효치료범위착，개체차이대，소이여하안전、합리사용화법림성위연구자관주적중점화난점。근년래적연구발현，기인다태성결정료화법림유효치료제량적개체차이。본문의종CYP2C9、VKORC1급APOE등기인다태성방면천술화법림대개체용약적영향。
Warfarin is one of the most widely prescribed oral anticoagulation in clinical practice. Since it has a narrow therapeutic range but a large individual variation,how to use it rational y and safely has been becoming a key problem in clinical practice.In recent years,the study found that the genetic polymorphisms which determined the individual dif erences of warfarin dose ef ective treatment. We reviewd the influences of genetic polymorphisms,such as CYP2C9、VKORC1 and APOE,on individualized medication of warfarin.